Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2022-11-22 Interim / Quarterly Rep…
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
CEO First Quarter Results and 2022 AGM Presentation 29 pages 2.0MB
Interim / Quarterly Report Classification · 95% confidence The document is a detailed presentation including operational highlights, financial results for the quarter ended September 30, 2022, and information related to the Annual General Meeting 2022. It contains financial data such as revenue, expenditure, cash burn, and loss before tax, as well as clinical pipeline updates and strategic information. The presence of detailed quarterly financial results and operational highlights indicates this is a comprehensive interim or quarterly report rather than a brief earnings release or a simple announcement. The document is about 15,000 characters long, which supports it being a full report rather than a short announcement. The title explicitly mentions 'Operational Highlights & Financial Results for the Quarter Ended September 30, 2022 and Annual General Meeting 2022,' but the content is primarily financial and operational results for the quarter, not just AGM materials or voting results. Therefore, the best fitting category is Interim / Quarterly Report (IR).
2022-11-22 English
MSB Q1 Financial Results and Operational Highlights 8 pages 452.6KB
Interim / Quarterly Report Classification · 95% confidence The document is a detailed report from Mesoblast Limited presenting financial results and operational highlights for the period ended September 30, 2022. It includes comprehensive financial data such as cash reserves, net cash usage, revenue, expenses, and loss after tax for the quarter, as well as operational updates on clinical trials and regulatory milestones. The presence of detailed financial figures, discussion of business operations, and forward-looking statements indicates this is a formal financial report rather than a brief announcement or presentation. The document length (15,000 characters) and content depth confirm it is not a short announcement or a transcript. Therefore, the document fits the definition of an Interim / Quarterly Report (IR), as it covers a period shorter than a full fiscal year with substantive financial data and analysis.
2022-11-22 English
Long-Term Survival for Acute GvHD Treatment with Remestemcel 3 pages 199.0KB
Capital/Financing Update Classification · 90% confidence The document is a press release announcing long-term survival results from a Phase 3 clinical trial of remestemcel-L for steroid-refractory acute graft versus host disease in children. It highlights key clinical trial outcomes, survival statistics, and the significance of these results for a Biologics License Application (BLA) resubmission to the FDA. The text is promotional and informational, focusing on clinical trial data and regulatory submission context, but it does not contain detailed financial statements, comprehensive management discussion, or full regulatory filings. It is not a full Annual Report, Interim Report, Earnings Release, or any detailed regulatory filing. It is also not a transcript, board change announcement, or legal proceeding report. The document is a corporate announcement of clinical trial results and regulatory update, typical of a Capital/Financing Update or general corporate update. Given the focus on clinical trial results and regulatory submission progress, the best fitting category is Capital/Financing Update (CAP), which includes updates on company fundraising, financing activities, or capital structure changes, and often includes significant clinical trial and regulatory progress announcements that impact company valuation and financing prospects. Confidence is high due to the clear nature of the document as a clinical trial result announcement tied to regulatory submission, not a formal financial or regulatory filing.
2022-11-22 English
Chairman's Address to Shareholders 3 pages 189.3KB
AGM Information Classification · 95% confidence The document is titled 'CHAIRMAN’S ADDRESS TO SHAREHOLDERS 2022 MESOBLAST ANNUAL GENERAL MEETING' and contains a speech from the chairman addressing shareholders at the AGM. It discusses company progress, regulatory updates, board changes, and thanks shareholders, which are typical contents of AGM presentations or materials. There is no detailed financial data or comprehensive report content that would classify it as an Annual Report (10-K) or Interim Report (IR). The document is not a transcript of a call, nor is it an announcement of voting results or a regulatory filing. The length (8820 characters) and content indicate it is a presentation or address given at the AGM, fitting the AGM Information category.
2022-11-22 English
Results of Meeting 3 pages 187.2KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Results of Annual General Meeting Held 23 November 2022' and contains detailed voting results for resolutions passed at the AGM, including proxy votes and poll results. It references compliance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001, which govern disclosure of voting results. The content is focused on the outcome of shareholder votes rather than the meeting materials or presentations. The document length is 5665 characters, which is sufficient to include detailed voting statistics. Therefore, this document is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-11-22 English
Mesoblast First Quarter Financial Results Webcast 1
Investor Presentation Classification · 85% confidence The document is a short announcement about an upcoming webcast to discuss financial results for the first quarter ended September 30, 2022. It provides details on the webcast timing, access link, and company background but does not contain actual financial statements or detailed financial data. The document length is only 2903 characters, which is quite short and consistent with an announcement rather than a full report. There is no detailed financial analysis or data that would classify it as an Interim/Quarterly Report (IR) or Earnings Release (ER). It is essentially a notice about a webcast event and financial results discussion, which fits best under Investor Presentation (IP) or possibly Regulatory Filings (RNS). However, since it is specifically about a webcast presentation of financial results and corporate update, the best fit is Investor Presentation (IP).
2022-11-20 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.